Variecolin - Compound Card

Variecolin

Select a section from the left sidebar

Variecolin

Structure
Zoomed Structure
  • Family: Fungi - Trichocomaceae
  • Kingdom: Fungi
  • Class: Terpenoid
    • Subclass: Sesterterpenoid
Canonical Smiles O=CC1=CC[C@H]2[C@@H]3[C@H](CC[C@@]3(C)CC[C@@]2(C[C@@H]2[C@H]1C(=O)C[C@@H]2C)C)C(=C)C
InChI InChI=1S/C25H36O2/c1-15(2)18-8-9-24(4)10-11-25(5)13-19-16(3)12-21(27)22(19)17(14-26)6-7-20(25)23(18)24/h6,14,16,18-20,22-23H,1,7-13H2,2-5H3/t16-,18+,19-,20-,22-,23-,24-,25+/m0/s1
InChIKey XAYQASOMEVLRKN-QFYAOFDFSA-N
Formula C25H36O2
HBA 2
HBD 0
MW 368.56
Rotatable Bonds 2
TPSA 34.14
LogP 5.77
Number Rings 4
Number Aromatic Rings 0
Heavy Atom Count 27
Formal Charge 0
Fraction CSP3 0.76
Exact Mass 368.27
Number of Lipinski Rule Violations 1
# Species Family Kingdom NCBI Taxonomy ID
1 Aspergillus japonicus Trichocomaceae Fungi 34381

Showing of synonyms

  • Jouda JB, Fopossi JD, et al. (2017). Secondary metabolites from Aspergillus japonicus CAM231, an endophytic fungus associated with Garcinia preussii.. Natural product research,2017, 31(8), 861-869. [View] [PubMed]
Pubchem: 6480205
Chebi: 66349
Metabolights: MTBLC66349
Bindingdb: 50260106

No compound-protein relationship available.

Structure

SMILES: O=C1CCC(C12)CC3C(CC=C2)C4C(CC3)CCC4

Level: 0

Mol. Weight: 368.56 g/mol

No bioactivities available.

Absorption

Caco-2 (logPapp)
-5.01
Human Oral Bioavailability 20%
Bioavailable
Human Intestinal Absorption
Absorbed
Madin-Darby Canine Kidney
-4.56
Human Oral Bioavailability 50%
Bioavailable
P-Glycoprotein Inhibitor
Non-Inhibitor
P-Glycoprotein Substrate
Non-Substrate
Skin Permeability
-1.84

Distribution

Blood-Brain Barrier (CNS)
-
Blood-Brain Barrier
Penetrable
Fraction Unbound (Human)
1.28
Plasma Protein Binding
67.83
Steady State Volume of Distribution
-

Metabolism

Breast Cancer Resistance Protein
Non-Inhibitor
CYP 1A2 Inhibitor
Non-Inhibitor
CYP 1A2 Substrate
Non-Substrate
CYP 2C19 Inhibitor
Non-Inhibitor
CYP 2C19 Substrate
Non-Substrate
CYP 2C9 Inhibitor
Non-Inhibitor
CYP 2C9 Substrate
Substrate
CYP 2D6 Inhibitor
Non-Inhibitor
CYP 2D6 Substrate
Non-Substrate
CYP 3A4 Inhibitor
Non-Inhibitor
CYP 3A4 Substrate
Non-Substrate
OATP1B1
Non-Inhibitor
OATP1B3
Non-Inhibitor

Excretion

Clearance
12.97
Organic Cation Transporter 2
Non-Inhibitor
Half-Life of Drug
-

Toxicity

AMES Mutagenesis
Safe
Avian
Safe
Bee
Toxic
Bioconcentration Factor
0.28
Biodegradation
Safe
Carcinogenesis
Safe
Crustacean
Toxic
Liver Injury I (DILI)
Safe
Eye Corrosion
Safe
Eye Irritation
Safe
Maximum Tolerated Dose
0.22
Liver Injury II
Toxic
hERG Blockers
Toxic
Daphnia Maga
6.42
Micronucleos
Safe
NR-AhR
Safe
NR-AR
Toxic
NR-AR-LBD
Safe
NR-Aromatase
Toxic
NR-ER
Safe
NR-ER-LBD
Safe
NR-GR
Safe
NR-PPAR-gamma
Safe
NR-TR
Safe
T. Pyriformis
-5.88
Rat (Acute)
4.13
Rat (Chronic Oral)
1.26
Fathead Minnow
3.92
Respiratory Disease
Safe
Skin Sensitisation
Toxic
SR-ARE
Toxic
SR-ATAD5
Safe
SR-HSE
Safe
SR-MMP
Safe
SR-p53
Safe

General Properties

Boiling Point
444.63
Hydration Free Energy
-3.13
Log(D) at pH=7.4
4.73
Log(P)
6.06
Log S
-5.35
Log(Vapor Pressure)
-7.21
Melting Point
127.29
pKa Acid
7.86
pKa Basic
5.1

No predicted protein targets found for this compound.

Download SDF